Unternehmen: Fresenius baut seine Beteiligung an Fresenius Medical Care ab
Fresenius reduziert die Anteile an dem Dialyseversorger um fast drei Prozent. Der Erlös aus dem Verkauf von etwa acht Millionen Aktien fließt nicht nur in mehr Wachstum.
Bad Homburg – Health conglomerate Fresenius has been reducing its stake in dialysis provider Fresenius Medical Care (FMC), disclosing that it has sold 7.8 million FMC shares, valued at approximately 300 million euros, to institutional investors following the closing bell on Thursday. This action brings Fresenius' shareholding down from 27.8% to roughly 25%.
CEO Michael Sen stated that this step provides additional flexibility to invest capital strategically into growth platforms. However, Fresenius also plans to use the proceeds to reduce its debt. Since taking office four years ago, Sen has been driving the restructuring of Fresenius, with a focus on its operational subsidiaries Kabi and Helios.
The most significant move was the deconsolidation of the former subsidiary FMC from the balance sheet three years ago, when Fresenius still held a 32.2% stake.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
